ChondroGene Inc. Announces Name Change To GeneNews
Published: Oct 23, 2006
TORONTO, Oct. 23 /PRNewswire-FirstCall/ - ChondroGene Limited announced today that the Company has changed its legal name to GeneNews Limited by filing Articles of Amendment on October 20, 2006.
The Company also reported that it expects its common shares will be listed on the Toronto Stock Exchange (TSX) and begin trading under the symbol 'GEN' at the open of trading on or about Thursday, October 26, 2006, subject to receiving final approval from the TSX. The Company also intends to de-list and cease trading of its common shares on the TSX Venture Exchange at close of trading on the trading day immediately preceding the anticipated listing on the TSX. The Company, therefore, expects that its common shares will continue to trade on the TSX Venture Exchange under the symbol 'CDG' until the close of trading on or about October 25, 2006.
ChondroGene received conditional approval to list its common shares on the TSX on September 20, 2006 and shareholder approval to change its name to GeneNews Limited at its last Annual Meeting held on June 12, 2006.
GeneNews (formerly ChondroGene Limited) is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a blood-based test that can detect colon cancer and pre-cancerous polyps. For more information on GeneNews, visit www.genenews.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release.ChondroGene Limited
CONTACT: Dr. K. Wayne Marshall, President & CEO, (416) 650-0060 x234,email@example.com; Bruno Maruzzo, Corporate Development, (416)650-0060 x237, firstname.lastname@example.org